Peptide data sheet
Eloralintide
GLP-1 · LY3841136
Verdict
promisinginvestigational weight management only
By MrPepTalks Editorial
Reviewed for scientific accuracy · research information, not medical advice
Last updated Reviewed
Quick answer
Eloralintide (LY3841136) is Eli Lilly's selective amylin receptor agonist, studied for weight management. Across a 48-week phase 2 trial in 263 adults, mean bodyweight change ranged from -9% to -20% by arm, against -0.4% on placebo. It is not FDA-approved; nausea and fatigue were the most commonly reported adverse events.
- Class
- Selective amylin receptor agonist (AMY1R-preferring)
- Half-life
- 310-366 hours (about 13-15 days) in phase 1
- FDA status
- Investigational, not approved (phase 2 complete, phase 3 ongoing)
Which form actually works?
Investigational clinical-trial drug (Eli Lilly)
Promising
The only form with human evidence behind it. This is the once-weekly formulation studied in Lilly's phase 1, 2 and 3 programmes, and only people enrolled in those trials have access to it.
Gray-market research vial
Risky
Vials advertised online as eloralintide sit outside any regulated chain of custody, so identity, purity and sterility are unverified. No published evidence covers material obtained this way, and the compound has no approved human use anywhere.
Third-Party Testing & Certificate of Analysis (COA)
A certificate of analysis (COA) is a lab document that reports what a specific batch of material actually contains. Reputable research suppliers publish one for every batch, tied to a lot number you can match against the vial you received.
- HPLC — purity
- High-performance liquid chromatography reports purity as a percentage: how much of the sample is the intended compound rather than impurities.
- Mass spectrometry (MS) — identity
- Mass spectrometry confirms identity by measuring the sample's molecular mass, so it matches the peptide the label names.
It also matters who ran the test. In-house results come from the seller's own lab; an independent third-party lab has no stake in the result, so its COA generally carries more weight. Look for a named testing laboratory, a batch or lot number, and a test date that lines up with the vial in hand.
New to reading one? This guide walks through a COA line by line: how to read a peptide COA.
Sources
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Dec 6;406(10520):2631-2643. PMID 41207310.
- Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025 Dec;102:102271. PMID 41109426 / PMCID PMC12640043.
- Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026 Apr;28(4):2651-2660. PMID 41559929.
- ClinicalTrials.gov NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (phase 2; 263 participants; completed 14 August 2025).
- ClinicalTrials.gov NCT07282600: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes (Eli Lilly; recruiting; started 15 December 2025, the earliest registered eloralintide phase 3 study).
- ClinicalTrials.gov NCT07321886: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes (recruiting; started 6 February 2026).
- PubChem CID 175663130: Eloralintide compound record (molecular formula C201H319N49O65S2, molecular weight 4526, InChIKey RLBIFQNAUXZCQB-UHFFFAOYSA-N).